Granules India's step-down subsidiary completes USFDA audit with zero observations

Published On 2023-03-21 09:25 GMT   |   Update On 2023-03-21 09:25 GMT

Hyderabad: Granules India has announced that Granules Consumer Health Inc., a stepdown subsidiary of the Company and a wholly owned subsidiary of Granules USA, Inc., has completed an audit by the U.S. Food and Drug Administration (US FDA) with zero 483s.The facility was inspected by the US FDA from 15th to 20th March 2023. “The audit is a pre-approval inspection for three products filed...

Login or Register to read the full article

Hyderabad: Granules India has announced that Granules Consumer Health Inc., a stepdown subsidiary of the Company and a wholly owned subsidiary of Granules USA, Inc., has completed an audit by the U.S. Food and Drug Administration (US FDA) with zero 483s.

The facility was inspected by the US FDA from 15th to 20th March 2023.

“The audit is a pre-approval inspection for three products filed from the facility. The packaging site strengthens our proposition to control the value chain and provides us with the agility needed in a very dynamic OTC space,” said Priyanka Chigurupati, Executive- Director, Granules USA, Inc. & Granules Pharmaceuticals, Inc.

Read also: Granules India bags USFDA okay for hypertension drug Losartan Potassium

Granules India Limited, incorporated in 1991 is a vertically integrated Indian pharmaceutical company headquartered in Hyderabad. Granules products are distributed to over 300+ customers in regulated and semi-regulated markets with a global presence extending to over 80+ countries with offices across India, US and UK. The Company has 7 manufacturing facilities out of which 6 are in India and 1 in USA and has regulatory approvals from US FDA, EDQM, EU GMP, COFEPRIS, WHO GMP, TGA, K FDA, DEA, MCC and HALAL. 

Read also: Granules Pharma bags USFDA nod for ADHD drug Amphetamine Mixed Salts ER

Tags:    

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News